Understanding Clonal Hematopoiesis in Kidney Cancer Could Improve Cardiovascular Outcomes
In a presentation at the 2023 International Kidney Cancer Symposium, Maxine Sun, PhD, MPH, discussed the relationship between clonal hematopoiesis in patients with kidney cancer and their risk for cardiac events.
Induction Chemotherapy Before Chemoradiation Betters Survival in Locally Advanced Cervical Cancer
Data presented at the 2023 ESMO Congress and showed that induction chemotherapy followed by chemoradiation reduced the risk of progression or death by 35% vs chemoradiation alone in patients with cervical cancer.
Disease Control Observed in ES-SCLC With Second-Line Sacituzumab Govitecan
Treatment with sacituzumab govitecan-hziy in the second line demonstrated responses in patients with extensive-stage small cell lung cancer, according to results from the phase 2 TROPiCS-03 trial.
Positive MRD Outcomes Seen With Isa-KRd in Newly Diagnosed, High-Risk Multiple Myeloma
The Isa-KRd combination in the GMMG-CONCEPT trial yielded high MRD negativity rates among patients with newly diagnosed, high-risk multiple myeloma, irrespective of transplant status.
Pemigatinib Shows Antitumor Activity in Tumors Harboring FGFR Alterations
Pemigatinib showed antitumor activity in patients with cholangiocarcinoma, central nervous system tumors, gynecologic tumors, and pancreatic cancer.
Phase 3 PhALLCON Trial of Ponatinib and Reduced-Intensity Chemo Shows Promise in Ph+ ALL
Findings from the phase 3 PhALLCON trial show that ponatinib plus reduced-intensity chemotherapy could be a new standard of care for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
Adding Pembrolizumab to Chemo Does Not Significantly Improve Survival in EGFR+ NSCLC
Data presented at the ASCO 2023 Annual Meeting showed that the addition of pembrolizumab to pemetrexed and platinum-based chemotherapy did not statistically improve survival in patients with TKI-resistant EGFR-mutated non–small cell lung cancer.
Cilta-cel Emerges With Potential to Change Practice in Select Patients With Lenalidomide-Refractory Myeloma
According to Binod Dhakal, MD, ciltacabtagene autoleucel may become a new standard therapy for patients with lenalidomide (Revlimid)-refractory multiple myeloma.
Elranatamab After Prior BCMA-Directed Therapy Induces Early Responses in RRMM
Pooled findings from MagnetisMM studies show the elranatamab has early activity in relapsed or refractory multiple myeloma.
Adjuvant Osimertinib Extends Survival in EGFR-Positive, Stage IB-IIIA NSCLC
ADAURA is the first global phase 3 study to demonstrate statistically significant and clinically meaningful disease-free survival and overall survival benefit with adjuvant targeted therapy for patients with EGFR-mutated, stage IB to IIIA NSCLC.
First-Line Osimertinib Displays Comparable Survival Outcomes Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLC
New results from the phase 2 APPLE trial shows how the use of osimertinib in the upfront setting compares with combination therapy in patients with EGFR-positive non–small cell lung cancer.
Toripalimab, Bevacizumab, and Chemo Elicits Responses in Refractory, Recurrent, or Metastatic Cervical Cancer
Toripalimab with bevacizumab and platinum-based chemotherapy showed promising response and disease control rates in patients with refractory, recurrent and metastatic cervical cancer.
First-line Treatment With Talazoparib and Enzalutamide Improves rPFS in mCRPC
Patients with first-line metastatic castration-resistant prostate cancer had improvements in radiographic progression-free survival irrespective of homologous recombination repair status when treated with talazoparib and enzalutamide.
Responses and Favorable Safety Shown With ADI-001 in Relapsed/Refractory B-Cell NHL
The first-in-human phase 1 trial of ADI-001 as a treatment for patients with relapsed/refractory B-cell non-Hodgkin lymphoma led to responses and a favorable safety profile.
OS Improvements Seen With First-Line Liposomal Irinotecan/NALIRIFOX in Metastatic PDAC
Findings from the phase 3 NAPOLI 3 trial support the NALIRIFOX regimen as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma.
Adagrasib With/Without Cetuximab Generates Responses in Advanced KRAS G12C–Mutated CRC
The use of adagrasib in combination with cetuximab or alone elicted encouraging responses in patients with advanced colorectal cancer harboring KRAS G12C mutations.
Tailoring Nivolumab and Ipilimumab Therapy Leads to Better Responses in RCC
A more tailored approach to treatment with PD-1 and CTLA-4 immune checkpoint blockade led to improved responses for patients with advanced renal cell carcinoma in both the first- and second-line settings, according to final results from the phase 2 TITAN-RCC trial.
Lasofoxifene Improves Certain Responses in ESR1-Mutated, ER+/HER2- Metastatic Breast Cancer
While lasfoxifene alone did not meet the primary end points that researchers set out for it, they did find that it improves responses in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.
Adding Oleclumab to Durvalumab and Chemotherapy Does Not Reach Clinical Benefit in Advanced TNBC
Oleclumab plus durvalumab and chemotherapy did not increase clinical benefit rate for patients with advanced triple-negative breast cancer, according to results from the phase 2 SYNERGY trial.
No Correlation Between Baseline Ocular Conditions and Belantamab Mafodotin-Induced Ocular Toxicity in Patients with R/R Myeloma
Post-hoc analysis findings from phase 2 DREAMM-2 trial show no relationship between ocular conditions found at baseline in patients with relapsed or refractory multiple myeloma and ocular toxicity from belantamab mafodotin.
Induction and Consolidation Therapy with Daratumumab Plus KRD Shows Potential in High-Risk Newly Diagnosed Myeloma
Daratumumab, carfilzomib, lenalidomide, and dexamethasone induction and consolidation allowed 70% of patients with high-risk, newly diagnosed multiple myeloma to complete a second autologous stem cell transplant.
Datopotamab Deruxtecan/Pembrolizumab Displays Responses With or Without Chemotherapy in Advanced NSCLC
Datopotamab deruxtecan and pembrolizumab with or without platinum-based chemotherapy showed promising efficacy and a manageable safety profile in advanced/metastatic non–small cell lung cancer without actionable genomic alterations.
GDC-6036 Monotherapy Reveals Promising Activity in KRAS G12C–Mutant NSCLC
A phase 1a trial of GDC-6036 showed encouraging antitumor activity with a manageable safety profile as a single agent in previously treated patients with KRAS G12C–mutated non–small cell lung cancer.
Patients With Previously Treated NSCLC Maintain OS Benefit With Tislelizumab
Overall survival benefit was sustained with second- or third-line tislelizumab in patients with non–small cell lung cancer vs docetaxel in the final analysis of the phase 3 RATIONALE-303 trial.
Improved PFS With Toripalimab Plus Chemotherapy in NSCLC Regardless of PD-L1 Status
Combination of toripalimab and chemotherapy in the frontline setting shows survival benefit in patients with advanced non–small cell lung cancer without EGFR or ALK mutations, regardless of PD-L1 status.
Encouraging Responses Demonstrated with Seribantumab in Solid Tumors Harboring NRG1 Fusions
Seribantumab elicited encouraging overall response rates and acceptable tolerability in patients with solid tumors harboring NRG1 fusions.
18F-rhPSMA-7.3 Increases Upstaging of Disease in Recurrent Prostate Cancer
Use of 18F-rhPSMA-7.3 PET results in post-scan upstaging compared with conventional imaging in patients with prostate cancer recurrence.
CAR T Cells Shown Effective Without Increased Risk of CRS or ICANS in CNS-Involved LBCL
Looking at 4 CAR T-cell agents for the treatment of large B-cell lymphoma, a systematic review and analysis showed that these therapies do not appear to increase the risk of cytokine release syndrome or immune effector cell–associated neurotoxicity syndrome.
Combo of BO-112 and Pembrolizumab Elicits Response in Advanced Melanoma
For advanced melanoma that is resistant to anti–PD-1 therapies, the addition of BO-112 to pembrolizumab appears to be effective and safe.
Fixed-Duration Ibrutinib Plus Venetoclax Hits Multiple Efficacy End Points in Study of High-Risk CLL/SLL
2 Clarke Drive Cranbury, NJ 08512